Inclusion Criteria:

          -  Patients with acute myeloid leukemia both flt3 positive and negative

          -  Human leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor
             available

          -  Life expectancy of at least 12 weeks (3 months)

          -  Direct bilirubin =< 1 mg/dL

          -  Alanine transaminase (ALT) =< 3 x upper limit of normal

          -  Serum creatinine =< 1.5 x the upper limit of normal

          -  Creatinine clearance >= 50

          -  Diffusing capacity for carbon monoxide (DLCO) > 50% of predicted corrected for
             hemoglobin

          -  Left ventricular ejection fraction (LVEF) >= 50%

          -  Subjects must be able to understand and be willing to sign the written informed
             consent form. A signed informed consent form must be appropriately obtained prior to
             the conduct of any trial-specific procedure

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of study drug. Post-menopausal women (defined as no
             menses for at least 1 year) and surgically sterilized women are not required to
             undergo a pregnancy test

          -  Subjects (men and women) of childbearing potential must agree to use adequate
             contraception beginning at the signing of the informed consent form (ICF) until at
             least 30 days after the last dose of study drug. The definition of adequate
             contraception will be based on the judgment of the principal investigator or a
             designated associate

          -  Subject must be able to swallow and retain oral medication

        Exclusion Criteria:

          -  Acute myeloid leukemia in first complete molecular remission and favorable risk
             disease as defined by presence of t(8:21) or inv (16)

          -  Patients with a comorbidity score > 3. The principal investigator is the final arbiter
             of eligibility for comorbidity score > 3

          -  Uncontrolled hypertension (systolic pressure > 140 mm Hg or diastolic pressure > 90 mm
             Hg [NCI-Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0] on
             repeated measurement) despite optimal medical management

          -  Active or clinically significant cardiac disease including: Congestive heart failure -
             New York Heart Association (NYHA) > class II. Active coronary artery disease. Cardiac
             arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
             Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before
             randomization, or myocardial infarction within 6 months before randomization

          -  Evidence or history of bleeding diathesis or coagulopathy. Patients with bleeding due
             to prior thrombocytopenia are permitted

          -  Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v. 4.0 grade 2 or
             higher within 4 weeks before randomization; any other hemorrhage/bleeding event of
             NCI-CTCAE v. 4.0 grade 3 or higher within 4 weeks before randomization

          -  Subjects with thrombotic, embolic, venous, or arterial cerebrovascular event
             (including transient ischemic attacks) within 6 months of informed consent

          -  Subjects who have used strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,
             phenobarbital, St. John's wort [Hypericum perforatum], dexamethasone at a dose of
             greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days
             before randomization

          -  Subjects with any previously untreated or concurrent cancer except cervical cancer
             in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects
             surviving a cancer that was curatively treated and without evidence of disease for
             more than 3 years before randomization are allowed. All cancer treatments must be
             completed at least 3 years prior to study entry (i.e., signature date of the informed
             consent form)

          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture

          -  History of organ allograft (including corneal transplant)

          -  Known or suspected allergy or hypersensitivity to any of the study drugs, study drug
             classes, or excipients of the formulations given during the course of this trial

          -  Any malabsorption condition

          -  Women who are pregnant or breast-feeding

          -  Inability to comply with the protocol and/or not willing or not available for
             follow-up assessments

          -  Any medical, psychological, or psychosocial condition which, in the investigator's
             opinion, makes the subject unsuitable for trial participation

          -  Major surgery within 30 days prior to start of study drug

          -  Patients who received inotuzumab and/or gemtuzumab in the past

          -  Therapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with
             heparins and heparinoids. However, prophylactic anticoagulation as described below is
             allowed: Low dose warfarin (1 mg orally, once daily) with prothrombin time
             international normalized ratio (PT-INR). =< 1.5 x upper limit of normal (ULN) is
             permitted. Infrequent bleeding or elevations in PT-INR have been reported in some
             subjects taking warfarin while on sorafenib or capecitabine therapy. Therefore,
             subjects taking concomitant warfarin should be monitored regularly for changes in PT,
             PT-INR or clinical bleeding episodes. Low dose aspirin (=< 100 mg daily). Prophylactic
             doses of heparin or low molecular weight heparin